Researchers from the Laboratory of Bioinformatics Approaches in Combinatorial Chemistry and Biology IBCH RAS, in collaboration with Irish colleagues, recently published a review in WIRES RNA that compiles the computational approaches, software tools, and data resources that have been developed over the last ten years for ribosome profiling data processing and analysis.

Monitoring of minimum residual disease (MRD) is one of the most important diagnostic tests in the treatment of acute and chronic lymphoblastic leukemia. Currently, several methods for MRD are used, the most sensitive of which is the assessment and monitoring of clonal rearrangements in the immunoglobulin genes characteristic of tumor cells. High sensitivity, up to 1 tumor cell per million, is achieved by using next generation highthroughput sequencing technology (Illumina).

Protein arginine methyltransferase 5 (PRMT5) belongs to the class II arginine methyltransferases and catalyzes monomethylation and symmetrical dimethylation of arginines on proteins. It has recently emerged as a promising cancer drug target, and two PRMT5 inhibitors are currently in clinical trials for a range malignancies. Despite the recognized therapeutic potential, it is unclear which PRMT5 functions underlie its oncogenic activity.

ICGEB Director-General Group Leader Lawrence Banks will deliver a lecture entitled «Human Papillomaviruses: From Infectious Entry to Malignancy».  Date and time: Mon 27 January 2020 14:00. Location: Small conference hall at 3rd floor BON IBCh.